These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 24353037

  • 1. Antiplatelet therapy: targeting the TxA2 pathway.
    Fontana P, Zufferey A, Daali Y, Reny JL.
    J Cardiovasc Transl Res; 2014 Feb; 7(1):29-38. PubMed ID: 24353037
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Difluorinated thromboxane A2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors.
    Allen MF, Hutchinson JL, Keith M, Mallah S, Corey RA, Trory JS, Jing C, Fang H, Wei L, Bennett SH, Aggarwal VK, Mundell SJ, Hers I.
    Br J Pharmacol; 2024 Oct; 181(19):3685-3699. PubMed ID: 38840293
    [Abstract] [Full Text] [Related]

  • 5. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R, Nenci GG, Gresele P.
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [Abstract] [Full Text] [Related]

  • 6. 1, 6-di-O-caffeoyl-β-D-glucopyranoside, a natural compound from Callicarpa nudiflora Hook impairs P2Y12 and thromboxane A2 receptor-mediated amplification of platelet activation and aggregation.
    Fu J, Zhu X, Wang W, Lu H, Zhang Z, Liu T, Xu H, Fu H, Ma S, Luo Y.
    Phytomedicine; 2017 Dec 01; 36():273-282. PubMed ID: 29157825
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R, Mezzasoma AM, Venditti G, Gresele P.
    Thromb Haemost; 2002 Jan 01; 87(1):114-21. PubMed ID: 11848439
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. From the design to the clinical application of thromboxane modulators.
    Dogné JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, Pirotte B, Ruan KH.
    Curr Pharm Des; 2006 Jan 01; 12(8):903-23. PubMed ID: 16533159
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The association of thromboxane A2 receptor with lipid rafts is a determinant for platelet functional responses.
    Moscardó A, Vallés J, Latorre A, Santos MT.
    FEBS Lett; 2014 Aug 25; 588(17):3154-9. PubMed ID: 24996187
    [Abstract] [Full Text] [Related]

  • 14. Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases.
    Mesitskaya DF, Syrkin AL, Aksenova MG, Zhang Y, Zamyatnin AA, Kopylov PY.
    Cardiovasc Hematol Agents Med Chem; 2018 Aug 25; 16(2):81-87. PubMed ID: 30039765
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Timosaponin AIII induces antiplatelet and antithrombotic activity via Gq-mediated signaling by the thromboxane A2 receptor.
    Cong Y, Wang L, Peng R, Zhao Y, Bai F, Yang C, Liu X, Wang D, Ma B, Cong Y.
    Sci Rep; 2016 Dec 09; 6():38757. PubMed ID: 27934923
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.